Related Experiment Videos
Therapeutic vaccines in autoimmunity
1Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel. michael.sela@weizmann.ac.il
Summary
Therapeutic vaccines, like Copolymer 1 for multiple sclerosis and peptide ligands for myasthenia gravis, show promise in treating autoimmune diseases by modulating immune responses. These treatments utilize specific molecules to suppress disease progression and reduce relapses.
Area of Science:
- Immunology
- Neuroimmunology
- Vaccinology
Background:
- Therapeutic vaccines leverage disease-specific antigens to modulate autoimmune responses.
- Multiple Sclerosis (MS) and Myasthenia Gravis (MG) are T-cell mediated autoimmune diseases.
Purpose of the Study:
- To describe therapeutic vaccine strategies for MS and MG.
- To highlight the mechanisms of action for Copolymer 1 (Cop 1) in MS and peptide ligands in MG.
Main Methods:
- Copolymer 1 (glatiramer acetate) development and clinical application in MS.
- Identification of immunodominant T-cell epitopes in the nicotinic acetylcholine receptor (AChR) for MG.
- Development of altered peptide ligands for MG treatment.
- Analysis of T-helper cell subsets (Th1, Th2) and regulatory cells (CD4(+)CD25(+)) in response to treatments.
Main Results:
- Cop 1 suppresses experimental allergic encephalomyelitis and is approved for relapsing-remitting MS, slowing disability and reducing relapses.
- Cop 1 induces T helper 2 (Th2) regulatory cells in MS patients and animal models.
- AChR-derived peptides are key T-cell targets in MG.
- Altered peptide ligands inhibit autoimmune responses in experimental MG via CD4(+)CD25(+) regulatory cells, downregulating Th1 cytokines and upregulating IL-10 and TGF-beta.
Conclusions:
- Therapeutic vaccines targeting disease-specific antigens offer a viable treatment strategy for autoimmune neurological disorders.
- Cop 1's efficacy in MS is linked to Th2 cell induction.
- Peptide-based immunotherapy, mediated by regulatory T cells, shows potential for treating MG.